FGB, TNFα, IL-1β, LPL, ITGB3, and TGFB1 genes polymorphism in patients with recurrent myocardial infarction

The aim. To evaluate the association of fibrinogen (FGB), tumor necrosis factor α (TNFα), interleukin 1β (IL-1β), lipoprotein lipase (LPL), platelet glycoprotein (ITGB3), and transforming growth factor β (TGFB1) genes  with the incidence of recurrent myocardial infarction (MI) in patients living in the middle Volga region.

Materials and methods. The study included 104 people with recurrent MI compared to 280 people who had just one episode of MI. TNFα (rs1800629), IL1B (rs16944), TGFB1b (rs1800469), FGB (rs1800788), ITGB3 (rs5918) and LPL (rs328) gene polymorphism was determined in all patients using competing TaqMan probes. Association estimation was performed with multivariate logistic regression analysis.

Results. Patients with recurrent MI much more often had TNFα, IL1B, TGFB1b, FGB, ITGB3 and LPL allele and 
genotype polymorphism. Moreover the risk of MI increased significantly in a case of combination of FGB (alleles and genotypes) and TNFα (alleles and genotypes) gene polymorphisms (OR = 4.04, 95% CI = (1.895–8.615), p = 0.0001).

Conclusion. Thus, FGB, LPL, TNFα, TGFB1b and ITGB3 gene polymorphism are associated with more severe 
coronary heart disease and may be a risk factor of recurrent MI development. The dominant total contribution of the FGB (rs1800788) and TNFα (rs1800629) polymorphic genes to the development of recurrent MI in the population of the middle Volga region was revealed.

1. Sukhija R., Fahdi I., Garza L., Fink L., Scott M., Aude W., Pacheco R., Bursac Z., Grant A., Mehta J.L. Inflammatory markers, angiographic severity of coronary artery disease, and patient outcome. Am. J. Cardiol. 2007; 99 (7): 879–884. DOI: 10.1016/j.amjcard.2006.11.032.

2. Koch W., Hoppmann P., Mueller J.C., Schömig A., Kastrati A. Association of transforming growth factor-β1 gene polymorphisms with myocardial infarction in patients with angiographically proven coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 2006; 26 (5): 1114–1119. DOI: 10.1161/01.ATV.0000217747.66517.11.

3. Miranda-Malpica E., Martínez-Rios M.A., Fragoso J.M., Delgadillo-Rodríguez H., Rodríguez-Pérez J.M., González- Quesada C., Martínez-Rodríguez N., Saldaña-Mendoza A., Peña-Duque M.A., Vargas-Alarcón G. The interleukin 1B–511 polymorphism is associated with the risk of developing restenosis after coronary stenting in Mexican patients. Hum. Immunol. 2008; 69 (2): 116–121. DOI: 10.1016/j.humimm.2007.12.003.

4. Mcpherson T.H., Tybjaerg-Hansen A. Genetics of coronary artery disease. Circ. Res. 2016; 118 (4): 564–578. DOI: 10.1161/CIRCRESAHA.115.306566.

5. Titov B.V., Osmak J., Matveeva N.A., Kukava G.N., Shakhnovich R.M., Favorov A.V., Ruda M.Y., Favorova O.O. Genetic risk factors for myocardial infarction more clearly manifest for early age of first onset. Mol. Biol. Rep. 2017; 44 (4): 315–321. DOI: 10.1007/s11033-017-4112-5.

6. Szalai C., Füst G., Duba J., Kramer J., Romics L., Prohászka Z., Császár A. Association of polymorphisms and allelic combinations in the tumour necrosis factor-alpha-complement MHC region with coronary artery disease. J. Med. Genet. 2002; 39 (1): 46–51. DOI: 10.1136/jmg.39.1.46.

7. Yang Y.N., Zhao B., Li X.M., Xie X., Liu F., Chen B.D. Association of a transforming growth factor-β1 polymorphism with acute coronary syndrome in a Chinese Han population. Mol. Res. 2014; 13 (3): 6160–6167. DOI: 10.4238/2014.April.3.2.

8. Jensen M.K., Rimm E.B., Rader D., Schmidt E.B., Sørensen T.I., Vogel U., Overvad K., Mukamal K.J. S447X variant of the lipoprotein lipase gene, lipids, and risk of coronary heart disease in 3 prospective cohort studies. Am. Heart J. 2009; 157 (2): 384–390. DOI: 10.1016/j.ahj.2008.10.008.

9. Verdoia M., Cassetti E., Schaffer A., Barbieri L., Giovine G.D., Nardin M., Marino P., Sinigaglia F., Luca G.D. Novara Atherosclerosis Study Group (NAS). Relationship between glycoprotein IIIa platelet receptor gene polymorphism and coronary artery disease. Angiology. 2015; 66 (1): 79–85. DOI: 10.1177/0003319714524296.

10. Tabrez S., Jabir N.R., Firoz C.K., Hindawi S., Shakil S., Damanhouri G.A., Zaidi S.K. Estimation of interleukin-1βpPromoter (−31 C/T and −511 T/C) polymorphisms and its level in coronary artery disease patients. J. Cell. Biochem. 2017; 118 (9): 2977–2982. DOI: 10.1002/jcb.25958.

11. Koch W., Kastrati A., Böttiger C., Mehilli J., von Beckerath N., Schömig A. Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis. 2001; 159 (1): 137–144. DOI: 10.1016/s0021-9150(01)00467-1.

12. Ahmadi Z., Senemar S., Toosi S., Radmanesh S. The Association of lipoprotein lipase genes, HindIII and S447X polymorphisms with coronary artery disease in Shiraz city. J. Cardiovasc. Thorac. Res. 2015; 7 (2): 63–67. DOI: 10.15171/jcvtr.2015.14.

13. Grove E.L., Ørntoft T.F., Lassen J.F., Jensen H.K., Kristensen S.D. The platelet polymorphism PlA2 is a genetic risk factor for myocardial infarction. J. Intern. Med. 2004; 255 (6): 637–644. DOI: 10.1111/j.1365-2796.2004.01327.x.